Kolong announced in a regulatory filing on the 12th that it has incorporated TONXBIO Inc., a company newly established through the human split-off (in-kind spin-off) of its existing subsidiary Kolon Pharmaceuticals, as a subsidiary. The incorporation date is October 2, 2026, based on the establishment registration date of the new entity.

40% Stake and Share Value of 16.4 Billion Won… Number of Subsidiaries Rises from 9 to 10

Kolong holds 532,544 shares of TONXBIO, accounting for 40.00% of the total issued shares. Following the incorporation, the share value is 16.422 billion won, representing 2.16% of Kolong's total assets. With this incorporation, the number of Kolong's subsidiaries has increased from the previous nine to ten.

Specialized in Pharmaceutical R&D… Representative Kim Sun-jin

TONXBIO is a company whose main business is pharmaceutical research and development, and its representative is Kim Sun-jin. According to its summary financial statements for the most recent fiscal year, total assets stand at 3.9672 billion won, total liabilities at 77 million won, and total capital at 3.8902 billion won, with capital stock of 665.6 million won.

Kolong explained that these financial figures were prepared based on the divided financial statements under the spin-off agreement of Kolon Pharmaceuticals. It also stated that the post-incorporation share value was calculated by allocating the book value of the pre-split entity according to the split ratio, and that the proportion relative to total assets was calculated based on Kolong's separate (non-consolidated) financial statements as of the end of 2025.